Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria. Initially confined to parts of Indonesia and Papua, resistance of P. vivax to CQ seems to be spreading, and alternative treatments are required. METHODS: We conducted a randomized controlled study to compare the efficacy and the tolerability of CQ and dihydroartemisinin-piperaquine (DP) in 500 adults and children with acute vivax malaria on the Northwestern border of Thailand. RESULTS: Both drugs were well tolerated. Fever and parasite clearance times were slower in the CQ than in the DP group (P < .001). By day 28, recurrent infections had emerged in 18 of 207 CQ recipients compared with 5 of 230 treated with DP (relative risk, 4.0; 95% confidence interval [CI], 1.51-10.58; P = .0046). The cumulative risk of recurrence with P. vivax at 9 weeks was 79.1% (95% CI, 73.5%-84.8%) in patients treated with CQ compared with 54.9% (95% CI, 48.2%-61.6%) in those receiving DP (hazard ratio [HR], 2.27; 95% CI, 1.8-2.9; P < .001). Children <5 years old were at greater risk of recurrent P. vivax infection (74.4%; 95% CI, 63.2%-85.6%) than older patients (55.3% [95% CI, 50.2%-60.4%]; HR, 1.58 [95% CI, 1.1-2.2]; P = .005). In vitro susceptibility testing showed that 13% of the tested isolates had a CQ median inhibitory concentration >100 nmol/L, suggesting reduced susceptibility. CONCLUSIONS: The efficacy of CQ in the treatment of P. vivax infections is declining on the Thai-Myanmar border. DP is an effective alternative treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The epidemiology of malaria in a Karen population on the western border of Thailand.
Luxemburger, C., Thwai, K. L., White, N. J., Webster, H. K., Kyle, D. E., Maelankirri, L., Chongsuphajaisiddhi, T., & Nosten, F. (1996) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(96)90102-9 · Cited by 233 · cited 1×
“Patients The study took place in the ShokloMalaria Research Unit clinics on the Thailand-Myanmar border, an area of low (entomologic inoculation rate, ,1) and seasonal malaria transmission[16].”
BackgroundSelf-citation
Cited by
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
Price, R. N., von Seidlein, L., Valecha, N., Nosten, F., Baird, J. K., & White, N. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70855-2 · Cited by 388
Self-citationCarrara, V. I., Lwin, K. M., Phyo, A. P., Ashley, E., Wiladphaingern, J., Sriprawat, K., Rijken, M., Boel, M., McGready, R., Proux, S., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001398 · Cited by 185
“vivax is becoming more resistant to chloroquine in this area [27], and this finding may explain the increasing proportion of patients presenting with vivax gametocytes (Figure 2).”
BackgroundSelf-citationMalaria ecology along the Thailand-Myanmar border.
Parker, D. M., Carrara, V. I., Pukrittayakamee, S., McGready, R., & Nosten, F. H. (2015) · Malaria Journal · doi:10.1186/s12936-015-0921-y · Cited by 142
“CRV appears to be widespread throughout vivax endemic regions [39].”
BackgroundSelf-citationThanapongpichat, S., McGready, R., Luxemburger, C., Day, N. P., White, N. J., Nosten, F., Snounou, G., & Imwong, M. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-275 · Cited by 32
“vivax [9].”
Self-citation
Metadata
- Authors
- Phyo, A. P., Lwin, K. M., Price, R. N., Ashley, E. A., Russell, B., Sriprawat, K., Lindegardh, N., Singhasivanon, P., White, N. J., & Nosten, F.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-10-14
- Volume
- 53
- Issue
- 10
- Pages
- 977-984
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2103971948
- Cited by
- 72
- References
- 1
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.